A surprising finding: GLP-1s role in PCOS

10 April 2024
biotech-research

Affecting one in 19 women, polycystic ovary syndrome (PCOS) remains understudied, with no dedicated treatments. Surprisingly, new diabetes and weight loss drugs may help.

A set of symptoms related to an imbalance of hormones that can affect women and girls of reproductive age,” according to  the National Institutes of Health (NIH). Symptoms can include hirsutism, menstrual disorders, polycystic ovaries, and infertility

PCOS is one of the most common causes of infertility in women- but it’s “underrecognized, underdiagnosed, and understudied,” says the NIH, while reports show poor understanding by physicians.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical